Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT06427798 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | recruiting | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 |
| clinicaltrials |
| NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer(ALISCA-Lung1) | recruiting | Phase 2 | 120 | Puma Biotechnology, Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06768307 | Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06377033 | Using the EHR to Advance Genomic Medicine Across a Diverse Health System | recruiting | N/A | 1,000 | University of PennsylvaniaOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT02688894 | The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S] | recruiting | — | 797 | Samsung Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04199741 | PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 | recruiting | Phase 1 / Phase 2 | 105 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05552846 | Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy | recruiting | N/A | 104 | Ruijin HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer(EVOKE-SCLC-04) | recruiting | Phase 3 | 695 | Gilead SciencesINDUSTRY | 23 | Aug 12, 2026 | clinicaltrials |
| NCT07155200 | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) | recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07759856 | NK Cells Plus ICI for SCLC Maintenance(NK-ICI-SCLC) | recruiting | Phase 2 | 42 | Tianjin First Central HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07759960 | Underwater Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Small Rectal Neuroendocrine Tumors | recruiting | N/A | 174 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06807632 | A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer | recruiting | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07151391 | The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue) | recruiting | Phase 2 | 86 | University of UtahOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT07545954 | DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07744256 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)(PULSE) | recruiting | Phase 4 | 107 | Anhui Provincial Cancer HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05443087 | TARGETed Therapy Drug MONITOring in DIGestive Oncology(TARGETMONITO) | recruiting | N/A | 330 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07129252 | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors(BRAVESST2) | recruiting | Phase 1 / Phase 2 | 150 | Crinetics Pharmaceuticals Inc.INDUSTRY | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07132645 | An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer | recruiting | Early Phase 1 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07402343 | Tarlatamab for SCLC Brain Metastases(T-BRAIN) | recruiting | Phase 2 | 35 | Maastricht University Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05263050 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | recruiting | Phase 2 | 111 | Fox Chase Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07339059 | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 35 | Bindu R PotugariOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06095583 | Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | recruiting | Phase 3 | 756 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 6 | Jul 27, 2026 | clinicaltrials |
| NCT07502300 | A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) | recruiting | Phase 3 | 562 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07728292 | Safety and Efficacy of Underwater Endoscopic Mucosal Resection for Type I Gastric Neuroendocrine Tumors Measuring 5-9 mm(POEM) | recruiting | N/A | 60 | Asian Institute of Gastroenterology, IndiaOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06038461 | An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06931626 | Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer | recruiting | Phase 1 | 10 | Nerviano Medical SciencesINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05882058 | DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | recruiting | Phase 2 | 204 | Boehringer IngelheimINDUSTRY | 12 | Jul 23, 2026 | clinicaltrials |
| NCT06437509 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 66 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06131840 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 914 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT07253142 | A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer | recruiting | Phase 2 | 120 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07559786 | A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy(ARL-LS-SCLC) | recruiting | Phase 2 | 200 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06398444 | A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms | recruiting | Phase 2 / Phase 3 | 85 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03892993 | Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers | recruiting | N/A | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05100095 | Hypofractionated Radiation Therapy for Merkel Cell Carcinoma | recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01365169 | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | recruiting | N/A | 590 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05652686 | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | recruiting | Phase 1 / Phase 2 | 203 | Phanes TherapeuticsINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05691465 | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05747729 | A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05889546 | Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer | recruiting | — | 30 | Indiana UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05628376 | TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO | recruiting | — | 600 | University College, LondonOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06876532 | Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour(LUTIBI) | recruiting | N/A | 150 | Institut Claudius RegaudOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07302347 | A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) | recruiting | Phase 1 / Phase 2 | 20 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06408402 | Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers(PGLEXPO2) | recruiting | — | 1,300 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2026source: clinicaltrials